You've got to love drug development. Where else can you see stocks double overnight?
The drugmaker will submit the data during the first quarter of next year and hopes it will have Nebido on the market by the end of the year. Ahh, what a difference a few months make!
Adding fuel to the fire, Indevus announced that it partnered with Teva Pharmaceuticals
I like Teva's move to expand the number of name-brand drugs it sells. The generics-plus strategy, which Mylan
Turning back to Indevus, while the pair of announcements last week are certainly good news and the company deserves the higher market cap (as I said it did in June), Indevus isn't out of the woods yet. The FDA has agreed to accept the data, but that's still a long way from an approval. And pagoclone has another phase 2 and a couple of phase 3 trials to go before we'll know if it'll be a success.
Indevus could easily double again from here, but with that potential for reward comes lots of risk. Tread lightly, Fools.